We are at www.bodyhealthfirst.com. Follow Us There! :)
A study team, sponsored in Bangladesh by Upazila Health & Family Planning Officer’s (UHFPO) Office, concluded that concerning the treatment outcome, adverse effect, and safety, the Ivermectin and Doxycycline the combination was superior to the use of Hydroxychloroquine and Azithromycin therapy in the case of a mild to moderate degree of COVID-19 patients. Although both treatment regimens were observed to be effective for this study, the Ivermectin treatment was superior. The Research team recently shared the results via the preprint server and ResearchGate.
Maybe you will also enjoy:
The investigators observed 181
patients who had tested positive for SARS-CoV-2 infection by RT PCR undertaken
at Cox’s Bazar Medical College. The participants were observed carefully for
family history and any comorbidities that could disqualify them for this study.
As it turned out, 42
participants had comorbid conditions that could impact recovery time; 14
participants were unwilling to participate in the study and 9 participants
failed to participate (3 from group A and 6 from group B) for follow up sample
collection so these were excluded.
Following exclusion, 116
patients were included with mild to moderate degree of illness with normal or
near-normal chest radiograph and Oxygen Saturation more than 95% were included
in this study. All the patients enrolled in the study were treated as an
outpatient protocol.
This controlled observational
study in Bangladesh produces some relatively compelling results. Patients
tested positive for COVID-19 are taking a combination of Ivermectin and
Doxycycline with a 100% success rate. On average, the mean symptomatic recovery
was 5.93 days with a disease that can stretch for two to three weeks.
According to “The Journal of
Antibiotics” several studies reported antiviral effects of ivermectin on RNA
viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle,
Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian
influenza A, Porcine Reproductive and Respiratory Syndrome, Human
immunodeficiency virus type 1, and severe acute respiratory syndrome
coronavirus 2.
Furthermore, there are some
studies showing antiviral effects of ivermectin against DNA viruses such as
Equine herpes type 1, BK polyomavirus, pseudorabies, porcine circovirus 2, and
bovine herpesvirus 1.
The blood levels of ivermectin at safe therapeutic doses are in the 20–80 ng/ml range, while the activity against SARS-CoV2 in cell culture is in the microgram range. Ivermectin is administered orally or topically. If safe formulations or analogs can be derived that can be administered to achieve therapeutic concentrations, ivermectin could be useful as a broad-spectrum antiviral agent. (https://www.nature.com/articles/s41429-020-0336-z).
Comments
Post a Comment
We will be glad to read a few words here!!! :)